This Thursday, Angelini Pharma has agreed to buy Catalyst Pharma for up to $4.1 billion, its first acquisition since 2021, which would mark its entry into the US market.
In other news today, having already committed last year to capital investments of $27 billion in the US to ward off the threat of tariffs, Eli Lilly has upped the ante.
Elsewhere, Roche has been working with US AI specialist PathAI for around five years, and has now upgraded that partnership with an offer to buy it for $1.05 billion.
Meanwhile, armed with new phase 3 data, Bayer is preparing to file a PET imaging agent that could accelerate the diagnosis of cardiac amyloidosis.
And life sciences service provider EVERSANA has named industry veteran Mike Guarino to lead its global health agency EVERSANA INTOUCH.